Last reviewed · How we verify
Butesin (BUTAMBEN)
Butesin works by interacting with the nervous system to reduce pain and itching sensations.
At a glance
| Generic name | BUTAMBEN |
|---|---|
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
ActionThe onset of OneTouch Advanced-produced anesthesia is rapid (approximately30 seconds) and the duration of anesthesia is typically 30-60 minutes, whenused as directed. This effect is due to the rapid onset, but short duration ofaction of Benzocaine coupled with the slow onset, but extended duration ofTetracaine HCI and bridged by the intermediate action of Butamben.It is believed that all of these agents act by reversibly blocking nerve conduc--tion. Speed and duration of action is determined by the ability of the agent tobe absorbed by the mucous membrane and nerve sheath and then to diffuseout, and ultimately be metabolized (primarily by plasma cholinesterases) to inertmetabolites which are excreted in the urine.
Approved indications
- Itching of skin
- Minor Skin Wound Pain
- Skin irritation
Common side effects
Key clinical trials
- A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis. (PHASE2)
- Efficacy of Pure Honey Dressing in Contrast to Alvogyl in the Resolution of Dry Socket (PHASE1)
- Chlorhexidine Gel Versus Alvogyl Following Surgical Extraction of Impacted Mandibular Third Molar (PHASE4)
- Clinical Effectiveness of Polymethoxy Flavones Solid Dispersion as a Dressing Material for Palatal Grafts Donor Sites (NA)
- Clinical Comparison of Topical Application of Alvogyl Versus Hyaluronic-Acid Gel in Management of Pain And Palatal Wound Healing (PHASE1)
- Alveogyl and Gelatin Sponge in the Management of Pain After Epithelialized Free Gingival Graft Harvesting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butesin CI brief — competitive landscape report
- Butesin updates RSS · CI watch RSS